REFERENCES
- Wallentin L, Becker RC, Budaj, et al. Ticagrelor versus Clopidogrel in
Patients with Acute Coronary Syndromes. N Engl J Med 2009;
61:1045-1057
- Serebruany VL.
Paradoxical excess
mortality in the PLATO trial should be independently verified.Thromb Haemost 2011;105:752-759.
- The FDA ticagrelor review of complete response. Available for download
at:
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf
Assessed June 15, 2020
- Neumann F-J, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS Guidelines on
myocardial revascularization. Eur Heart J 2019; 40: 87–165
- Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular
Society/Canadian Association of Interventional Cardiology Focused
Update of the Guidelines for the Use of Antiplatelet Therapy.Can J Cardiol 2018;34:214-233
- Levine GN, Bates ER, Bittle JA. et al. ACC/AHA Guideline Focused
Update on Duration of Dual Antiplatelet Therapy in Patients With
Coronary Artery Disease. JACC; 2016; 68:1082–1115
- Serebruany V, Tanguay J-F, Benavides MA, et al. Verifying Death
Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.Amer J Therap 2020; 27:e563-e572
- DiNicolantonio JJ, Tomek A.
Misrepresentation
of vital status follow-up: challenging the integrity of the PLATO
trial and the claimed mortality benefit of ticagrelor versus
clopidogrel. Int J Cardiol 2013;169:145-146
- Varenhorst C, Alström U, Braun OO, et
al. Causes of mortality with ticagrelor compared with clopidogrel in
acute coronary syndromes. Heart 2014;100:1762-1769
- Storey RF, James
SK, Siegbahn
A, et al. Lower mortality following pulmonary adverse events and
sepsis with ticagrelor compared to clopidogrel in the PLATO study.
Platelets 2014;25:517-525
Table. Primary deaths causes in the FDA- and PLATO
Investigators datasets